RT Journal Article
T1 Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations.
A1 Forbes, Lisa R
A1 Vogel, Tiphanie P
A1 Cooper, Megan A
A1 Castro-Wagner, Johana
A1 Schussler, Edith
A1 Weinacht, Katja G
A1 Plant, Ashley S
A1 Su, Helen C
A1 Allenspach, Eric J
A1 Slatter, Mary
A1 Abinun, Mario
A1 Lilic, Desa
A1 Cunningham-Rundles, Charlotte
A1 Eckstein, Olive
A1 Olbrich, Peter
A1 Guillerman, R Paul
A1 Patel, Niraj C
A1 Demirdag, Yesim Y
A1 Zerbe, Christa
A1 Freeman, Alexandra F
A1 Holland, Steven M
A1 Szabolcs, Paul
A1 Gennery, Andrew
A1 Torgerson, Troy R
A1 Milner, Joshua D
A1 Leiding, Jennifer W
AB Treatment of the autoimmune and immune-dysregulatory features of patients with STAT1 GOF or STAT3 GOF disease remains challenging. Jakinibs have been used to treat the severe immune-dysregulation in patients with either STAT1 GOF or STAT3 GOF mutations.
YR 2018
FD 2018-08-06
LK http://hdl.handle.net/10668/12815
UL http://hdl.handle.net/10668/12815
LA en
DS RISalud
RD Apr 6, 2025